eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2024
vol. 28
 
Share:
Send email
Share:
Original paper

P-selectin glycoprotein ligand-1 is diversely expressed in the primary tumour and venous thrombus of clear cell renal cancer and correlates with poor overall survival

Rafał Pęksa
1
,
Sumit Sharma
2
,
Michał Kunc
1
,
Marta Popęda
1
,
Le Qu
3, 4
,
Mikołaj Frankiewicz
5
,
Marcin Folwarski
6, 7
,
Piotr Radziszewski
2
,
Łukasz Zapała
2

  1. Department of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland
  2. Clinic of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland
  3. Department of Urology Jinling Hospital Affiliated Hospital of Medical School Nanjing University, Nanjing Jiangsu, China
  4. Department of Urology Jinling Hospital Jinling School of Clinical Medicine Nanjing Medical University, Nanjing Jiangsu, China
  5. Department of Urology, Medical University of Gdańsk, Gdańsk, Poland
  6. Department of Clinical Nutrition and Dietetics, Medical University of Gdańsk, Gdańsk, Poland
  7. Home Enteral and Parenteral Nutrition Unit, General Surgery Department, Nicolaus Copernicus Hospital, Gdańsk, Poland
Contemp Oncol (Pozn) 2024; 28 (3): 253–259
DOI: https://doi.org/10.5114/wo.2024.144225
Online publish date: 2024/10/15
Article file
- P-selectin glycoprotein (1).pdf  [0.37 MB]
Get citation
 
PlumX metrics:
 
1. Antonelli A, Sodano M, Sandri M, et al. Venous tumor thrombus consistency is not predictive of survival in patients with renal cell carcinoma: a retrospective study of 147 patients. Int J Urol 2015; 22: 534-539.
2. Berczi A, Flasko T, Szerafin T, Thomas B, Bacso Z, Berczi C. Surgical management and outcome of renal cell carcinoma with inferior vena cava tumor thrombus. Urol Int 2017; 99: 267-271.
3. Borregales LD, Adibi M, Thomas AZ, Wood CG, Karam JA. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol 2016; 8: 130-141.
4. Carretero-Gonzalez A, Lora D, Martin Sobrino I, et al. The value of PD-L1 expression as predictive biomarker in metastatic renal cell carcinoma patients: a meta-analysis of randomized clinical trials. Cancers (Basel) 2020; 12: 1945.
5. Lavacchi D, Pellegrini E, Palmieri VE, et al. Immune checkpoint inhibitors in the treatment of renal cancer: current state and future perspective. Int J Mol Sci 2020; 21: 4691.
6. Zapala L, Kunc M, Sharma S, et al. Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell carcinoma with venous tumor thrombus. J Cancer Res Clin Oncol 2023; 149: 4131-4139.
7. Zapala L, Kunc M, Sharma S, et al. Evaluation of PD-L1 (E1L3N, 22C3) expression in venous tumor thrombus is superior to its assessment in renal tumor in predicting overall survival in renal cell carcinoma. Urol Oncol 2022; 40: 200 e1- e10.
8. Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer 2019; 18: 155.
9. Hong S, Yuan Q, Xia H, et al. Establishment of an ex vivo tissue culture model for evaluation of antitumor efficacy in clear cell renal cell carcinoma. Front Oncol 2022; 12: 851191.
10. Johnston RJ, Su LJ, Pinckney J, et al. VISTA is an acidic pH-selective ligand for PSGL-1. Nature 2019; 574: 565-570.
11. Russo HM, Wickenheiser KJ, Luo W, et al. P-selectin glycoprotein ligand-1 regulates adhesive properties of the endothelium and leukocyte trafficking into adipose tissue. Circ Res 2010; 107: 388-397.
12. Sreeramkumar V, Adrover JM, Ballesteros I, et al. Neutrophils scan for activated platelets to initiate inflammation. Science 2014; 346: 1234-1238.
13. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors, ed. U.I.U.A., Wiley-Blackwell: Hoboken, NJ, USA 2009, 7.
14. Koppel C, Schwellenbach H, Zielinski D, et al. Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms. Mod Pathol 2018; 31: 1630-1644.
15. Team RC. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2020.
16. Kassambara AK, Biecek M, Survminer P. Drawing survival curves using “ggplot2”. R Package Version 048 2020. 2020.
17. Kappelmayer J, Nagy B Jr. The interaction of selectins and PSGL-1 as a key component in thrombus formation and cancer progression. Biomed Res Int 2017; 2017: 6138145.
18. Yamaoka T, Fujimoto M, Ogawa F, et al. The roles of P- and E-selectins and P-selectin glycoprotein ligand-1 in primary and metastatic mouse melanomas. J Dermatol Sci 2011; 64: 99-107.
19. Lin Y, Huang S, Qi Y, et al. PSGL-1 is a novel tumor microenvironment prognostic biomarker with cervical high-grade squamous lesions and more. Front Oncol 2023; 13: 1052201.
20. Ramos-Sevillano E, Yuste J. Novel therapeutic strategies against cancer and chronic infection by targeting P-selectin glycoprotein ligand-1 as an immune T cells response regulator. Translat Cancer Res 2016; 5: s868-71.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.